Evidence map›Paper›PMID 27764105›Full record

SynthesisPloS one2016

Genome-Wide Meta-Analysis of Sciatica in Finnish Population.

Susanna Lemmelä, Svetlana Solovieva, Rahman Shiri, Christian Benner, Markku Heliövaara, Johannes Kettunen, Verneri Anttila, Samuli Ripatti, Markus Perola, Ilkka Seppälä and 9 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 4 countries.

Susanna LemmeläHealth and Work Ability, Finnish Institute of Occupational Health, 00250 Helsinki, Finland.
Svetlana SolovievaHealth and Work Ability, Finnish Institute of Occupational Health, 00250 Helsinki, Finland.
Rahman ShiriHealth and Work Ability, Finnish Institute of Occupational Health, 00250 Helsinki, Finland.
Christian BennerInstitute for Molecular Medicine Finland (FIMM), 00014 University of Helsinki, Helsinki, Finland.
Markku HeliövaaraPopulation Health Unit, National Institute for Health and Welfare, 00251 Helsinki, Finland.
Johannes KettunenFaculty of Medicine, Institute of Health Sciences, University of Oulu, 90220 Oulu, Finland.
Verneri AnttilaAnalytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, United States of America.
Samuli RipattiInstitute for Molecular Medicine Finland (FIMM), 00014 University of Helsinki, Helsinki, Finland.
Markus PerolaInstitute for Molecular Medicine Finland (FIMM), 00014 University of Helsinki, Helsinki, Finland.
Ilkka SeppäläDepartment of Clinical Chemistry, Fimlab Laboratories, University of Tampere School of Medicine, 33520 Tampere, Finland.
Markus JuonalaDivision of Medicine, Turku University Hospital, 20521 Turku, Finland.
Mika KähönenDepartment of Clinical Physiology, Tampere University Hospital, 33521 Tampere, Finland.
Veikko SalomaaDepartment of Health, National Institute for Health and Welfare, 00251 Helsinki, Finland.
Jorma ViikariDivision of Medicine, Turku University Hospital, 20521 Turku, Finland.
Olli T RaitakariResearch Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, 20520 Turku, Finland.
Terho LehtimäkiDepartment of Clinical Chemistry, Fimlab Laboratories, University of Tampere School of Medicine, 33520 Tampere, Finland.
Aarno PalotieInstitute for Molecular Medicine Finland (FIMM), 00014 University of Helsinki, Helsinki, Finland.
Eira Viikari-JunturaDisability Prevention Centre, Finnish Institute of Occupational Health, 00250 Helsinki, Finland.
Kirsti Husgafvel-PursiainenHealth and Work Ability, Finnish Institute of Occupational Health, 00250 Helsinki, Finland.
Finnish Institute of Occupational Health · FITampere University · FIFinnish Institute for Health and Welfare · FITurku University Hospital · FIUniversity of Helsinki · FIBroad Institute · USInstitute for Molecular Medicine Finland · FIMassachusetts General Hospital · USUniversity of Oulu · FIUniversity of Turku · FI

Funding

Wellcome Trust 098051
6 · The paper itself

Abstract

Sciatica or the sciatic syndrome is a common and often disabling low back disorder in the working-age population. It has a relatively high heritability but poorly understood molecular mechanisms. The Finnish population is a genetic isolate where small founder population and bottleneck events have led to enrichment of certain rare and low frequency variants. We performed here the first genome-wide association (GWAS) and meta-analysis of sciatica. The meta-analysis was conducted across two GWAS covering 291 Finnish sciatica cases and 3671 controls genotyped and imputed at 7.7 million autosomal variants. The most promising loci (p<1x10-6) were replicated in 776 Finnish sciatica patients and 18,489 controls. We identified five intragenic variants, with relatively low frequencies, at two novel loci associated with sciatica at genome-wide significance. These included chr9:14344410:I (rs71321981) at 9p22.3 (NFIB gene; p = 1.30x10-8, MAF = 0.08) and four variants at 15q21.2: rs145901849, rs80035109, rs190200374 and rs117458827 (MYO5A; p = 1.34x10-8, MAF = 0.06; p = 2.32x10-8, MAF = 0.07; p = 3.85x10-8, MAF = 0.06; p = 4.78x10-8, MAF = 0.07, respectively). The most significant association in the meta-analysis, a single base insertion rs71321981 within the regulatory region of the transcription factor NFIB, replicated in an independent Finnish population sample (p = 0.04). Despite identifying 15q21.2 as a promising locus, we were not able to replicate it. It was differentiated; the lead variants within 15q21.2 were more frequent in Finland (6-7%) than in other European populations (1-2%). Imputation accuracies of the three significantly associated variants (chr9:14344410:I, rs190200374, and rs80035109) were validated by genotyping. In summary, our results suggest a novel locus, 9p22.3 (NFIB), which may be involved in susceptibility to sciatica. In addition, another locus, 15q21.2, emerged as a promising one, but failed to replicate.

Indexed as

Genome-Wide Association StudyCase-Control StudiesChromosomes, Human, Pair 15Chromosomes, Human, Pair 6Chromosomes, Human, Pair 9Databases, FactualDisease SusceptibilityFinlandGene FrequencyGenotypeHumansNFI Transcription FactorsPolymorphism, Single NucleotideSciaticaWhite PeopleNFIB protein, humanNFI Transcription Factors

Identifiers

PMID27764105
PMCPMC5072673
OpenAlexW2534260887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.